Schneck JP - Search Results

1

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C. Bruns H, et al. Among authors: schneck jp. Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15. Clin Cancer Res. 2015. PMID: 25593301 Free PMC article.

2

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Oelke M, et al. Among authors: schneck jp. Nat Med. 2003 May;9(5):619-24. doi: 10.1038/nm869. Epub 2003 Apr 21. Nat Med. 2003. PMID: 12704385

3

HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.

Oelke M, Schneck JP. Oelke M, et al. Among authors: schneck jp. Clin Immunol. 2004 Mar;110(3):243-51. doi: 10.1016/j.clim.2003.11.014. Clin Immunol. 2004. PMID: 15047202 Review.

4

Quality and quantity: new strategies to improve immunotherapy of cancer.

Krueger C, Schneck JP, Oelke M. Krueger C, et al. Among authors: schneck jp. Trends Mol Med. 2004 May;10(5):205-8. doi: 10.1016/j.molmed.2004.03.004. Trends Mol Med. 2004. PMID: 15121045

5

Technological advances in adoptive immunotherapy.

Oelke M, Krueger C, Schneck JP. Oelke M, et al. Among authors: schneck jp. Drugs Today (Barc). 2005 Jan;41(1):13-21. doi: 10.1358/dot.2005.41.1.875775. Drugs Today (Barc). 2005. PMID: 15753966 Review.

6

Artificial antigen-presenting cells: artificial solutions for real diseases.

Oelke M, Krueger C, Giuntoli RL 2nd, Schneck JP. Oelke M, et al. Among authors: schneck jp. Trends Mol Med. 2005 Sep;11(9):412-20. doi: 10.1016/j.molmed.2005.07.005. Trends Mol Med. 2005. PMID: 16103011 Review.

7

Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis.

Boin F, Wigley FM, Schneck JP, Oelke M, Rosen A. Boin F, et al. Among authors: schneck jp. Ann N Y Acad Sci. 2005 Dec;1062:137-45. doi: 10.1196/annals.1358.016. Ann N Y Acad Sci. 2005. PMID: 16461796

8

Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Schütz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Schütz C, et al. Among authors: schneck jp. Blood. 2008 Apr 1;111(7):3546-52. doi: 10.1182/blood-2007-09-113522. Epub 2007 Dec 20. Blood. 2008. PMID: 18096763 Free PMC article.

9

In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP. Durai M, et al. Among authors: schneck jp. Cancer Immunol Immunother. 2009 Feb;58(2):209-20. doi: 10.1007/s00262-008-0542-1. Epub 2008 Jun 18. Cancer Immunol Immunother. 2009. PMID: 18563409 Free PMC article.

10

Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Webb TJ, Giuntoli RL 2nd, Rogers O, Schneck J, Oelke M. Webb TJ, et al. Clin Cancer Res. 2008 Dec 1;14(23):7652-8. doi: 10.1158/1078-0432.CCR-08-1468. Clin Cancer Res. 2008. PMID: 19047090 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters